Skip to content
HowShorted

MADRIGAL PHARMACEUTICALS, INC. short interest in 2025

In 2025, MADRIGAL PHARMACEUTICALS, INC.'s disclosed short interest ran from 18.72% of shares outstanding on 15 Jan 2025 to 16.34% on 31 Dec 2025, a change of -2.38 percentage points. The year's high was 18.77% on 14 Mar 2025 and its low 16.34% on 31 Dec 2025, averaging 17.58% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 16.96 days on 31 Mar 2025. Full history: MADRIGAL PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for MADRIGAL PHARMACEUTICALS, INC. in 2025

2025 in figures

Start of year
18.72% (15 Jan 2025)
End of year
16.34% (31 Dec 2025)
Change
-2.38 pp
High
18.77% (14 Mar 2025)
Low
16.34% (31 Dec 2025)
Average
17.58%
Highest days to cover
16.96 (31 Mar 2025)
SEC filings marked
9

Every report in 2025

MADRIGAL PHARMACEUTICALS, INC. short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 202518.72%8.98results (8-K)
31 Jan 202518.26%8.56
14 Feb 202517.40%10.70
28 Feb 202517.21%8.7110-K filed, results (8-K)
14 Mar 202518.77%8.53
31 Mar 202518.33%16.96
15 Apr 202518.46%11.51
30 Apr 202518.49%11.43
15 May 202518.02%10.3310-Q filed, results (8-K)
30 May 202517.50%12.08
13 Jun 202518.70%13.88
30 Jun 202517.87%12.18
15 Jul 202517.06%16.04
31 Jul 202517.93%8.83
15 Aug 202517.02%8.3610-Q filed, results (8-K)
29 Aug 202518.16%9.29
15 Sep 202518.56%12.75
30 Sep 202516.70%10.88
15 Oct 202516.55%13.94
31 Oct 202516.45%12.67
14 Nov 202516.67%7.3810-Q filed, results (8-K)
28 Nov 202516.38%9.96
15 Dec 202516.37%14.03
31 Dec 202516.34%13.07

See also: MADRIGAL PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.